Gravar-mail: Phase I/II trial of liver–derived mesenchymal stem cells in pediatric liver–based metabolic disorders : a prospective, open label, multicenter, partially randomized, safety study of one cycle of heterologous human adult liver–derived progenitor cells (HepaStem) in urea cycle disorders and Crigler-Najjar syndrome patients